Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Spero Therapeutics (SPRO) granted equity awards to new employees under its 2019 Inducement Equity Incentive Plan, effective September 1, 2026.

Rhea-AI Summary

Spero Therapeutics (SPRO) granted equity awards to new employees under its 2019 Inducement Equity Incentive Plan, effective September 1, 2026.

The Compensation Committee approved an aggregate of 102,000 restricted stock units (RSUs) and 67,600 stock options as inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). The plan is used solely for individuals who were not previously employed by Spero, or rejoin after a bona fide break in service. Stock options vest 25% on September 1, 2027, with the balance vesting in 36 equal monthly installments thereafter, while RSUs vest in four equal annual installments starting September 1, 2027, in each case subject to continued employment and the plan and award agreements.

Market Context

SPRO's August 5 inducement-grant announcement had a 0.79% 24-hour reaction. This grant disclosed 102...

Analysis

SPRO's August 5 inducement-grant announcement had a 0.79% 24-hour reaction. This grant disclosed 102,000 RSUs and 67,600 options; the August 28 S-3 is not effective, making subsequent shelf usage worth monitoring.

Key Figures

RSU awards: 102,000 RSUs Stock options: 67,600 stock options Grant date: September 1, 2026 +3 more

6 metrics

RSU awards 102,000 RSUs Grant approved September 1, 2026

Stock options 67,600 stock options Grant approved September 1, 2026

Grant date September 1, 2026 Inducement equity grant

Initial option vesting 25% Vests on September 1, 2027

Remaining option vesting 36 equal monthly installments After the initial 25% vesting

RSU vesting Four equal annual installments Beginning September 1, 2027

Historical Context

5 past events · Latest: Aug 12 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 12	2Q26 earnings report	Neutral	+4.2%	Quarterly results, FDA approval, financing, licensing, and cash runway update
Aug 05	Inducement equity grant	Neutral	+0.8%	New employee received options and restricted stock units under Nasdaq exemption
Aug 04	Earnings date announcement	Neutral	+2.4%	Company scheduled second-quarter results and business update for August 12
Jul 27	Leadership appointment	Positive	-0.8%	Debra Jeske Zack appointed chief medical officer to lead clinical development
Jul 14	Royalty financing	Positive	-22.0%	Company announced $105 million non-dilutive royalty financing and SP001 license

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive and neutral announcements produced mixed reactions, including a 22.02% decline after the July 14 financing announcement.

Key Terms

rsus, nasdaq listing rule 5635(c)(4)

2 terms

rsus financial

"102,000 restricted stock unit awards (RSUs) and 67,600 stock options"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that the Compensation Committee of Spero’s Board of Directors approved a grant, made on September 1, 2026, of an aggregate of 102,000 restricted stock unit awards (RSUs) and 67,600 stock options to new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan). The stock options and RSUs are being granted as an inducement material to Spero’s new employees in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Spero (or following a bona fide period of non-employment), as a material inducement for such individuals entering into employment with Spero, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

The shares underlying the option vest as to 25% on September 1, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the employee’s continued employment with Spero through the applicable vesting dates. The RSUs will vest in four equal annual installments beginning on September 1, 2027, subject to the employees' continued employment with Spero through the applicable vesting dates. The stock options and the RSUs are subject to the terms and conditions of the 2019 Inducement Plan and the stock option and the RSU agreement covering the grant.

About Spero Therapeutics
Spero Therapeutics is a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for patients with serious immune-mediated diseases. The company’s lead program, SP001, is a third-generation, Fc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related disease, with potential for development in additional immunological & inflammatory diseases. For more information, visit www.sperotx.com

Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@Sperotx.com

Media Inquiries:
media@sperotx.com

FAQ

What equity awards did Spero Therapeutics (SPRO) grant under Nasdaq Listing Rule 5635(c)(4)?

Spero Therapeutics granted an aggregate of 102,000 restricted stock units (RSUs) and 67,600 stock options to new employees under its 2019 Inducement Equity Incentive Plan as inducement awards.

Who is eligible for the new Spero Therapeutics (SPRO) inducement equity grants?

The 2019 Inducement Equity Incentive Plan is used exclusively for equity awards to individuals who were not previously employees of Spero, or who return after a bona fide period of non-employment, as a material inducement to enter into employment.

What is the vesting schedule for the new Spero Therapeutics (SPRO) stock options granted September 1, 2026?

The stock options vest 25% on September 1, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the employee’s continued employment and the terms of the plan and option agreement.

How do the RSUs granted by Spero Therapeutics (SPRO) on September 1, 2026 vest?

The RSUs will vest in four equal annual installments beginning on September 1, 2027, provided the employees remain continuously employed with Spero and comply with the terms and conditions of the 2019 Inducement Plan and the related RSU agreements.

Why did Spero Therapeutics (SPRO) issue RSUs and stock options under the 2019 Inducement Plan?

The company issued these RSUs and stock options as a material inducement for new employees to join Spero, in line with Nasdaq Listing Rule 5635(c)(4), which allows equity grants outside shareholder-approved plans for new hires under specified conditions.